FIFTY NORTHERN AVENUE LLC AND VERTEX PHARMACEUTICALS INCORPORATED LEASE FOR 50 NORTHERN AVENUE (PARCEL A – FAN PIER) BOSTON, MASSACHUSETTSVertex Pharmaceuticals Incorporated • July 30th, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
Date of Lease: May 5, 2011 Landlord: Fifty Northern Avenue LLC, a Delaware limited liability company Tenant: Vertex Pharmaceuticals Incorporated, a Massachusetts corporation Address of Property: Parcel A, Fan Pier, Boston, MA, subject to the provisions of Section 2.01(c) 1.05.Building, Property and Project: The 15-story building to be constructed by Landlord and containing, upon completion, approximately [***] rentable square feet (the “Building”) in the City of Boston, Massachusetts, located on a parcel of land described in Exhibit 1.05 attached hereto and known as Parcel A, Fan Pier, Boston, Massachusetts (the Building and such parcel of land hereinafter being collectively referred to as the “Property”). The Property is part of a phased development located in the South Boston waterfront area of Boston, Massachusetts, currently consisting of nine (9) lettered parcels to be developed separately with up to nine (9) new buildings, projected to have an aggregate of approximately [***] squ
ELEVEN FAN PIER BOULEVARD LLC AND VERTEX PHARMACEUTICALS INCORPORATED LEASE FOR 11 FAN PIER BOULEVARD (PARCEL B — FAN PIER) BOSTON, MASSACHUSETTSVertex Pharmaceuticals Inc / Ma • July 30th, 2021 • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDED AND RESTATED JOINT...Joint Development and Commercialization Agreement • July 30th, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of April 16, 2021 (the “Amendment Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales (“CRISPR UK”), and TRACR Hematology Ltd, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK, “CRISPR”), and amends and restates that ce
